Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA2372133
Max Phase: Preclinical
Molecular Formula: C69H87N13O23S
Molecular Weight: 1498.59
Molecule Type: Unknown
Associated Items:
ID: ALA2372133
Max Phase: Preclinical
Molecular Formula: C69H87N13O23S
Molecular Weight: 1498.59
Molecule Type: Unknown
Associated Items:
Canonical SMILES: C[C@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(=O)O)NC(=O)[C@@H]1CCCN1C(=O)CCCCNC(=S)Nc1ccc2c(c1)C1(OC2=O)c2ccc(O)cc2Oc2cc(O)ccc21)[C@@H](C)O)C(=O)N1CCCC[C@H]1C(=O)N1C[C@H](ON)C[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(N)=O
Standard InChI: InChI=1S/C69H87N13O23S/c1-34(64(99)81-26-6-4-9-49(81)66(101)82-33-39(105-71)32-50(82)62(97)76-45(20-23-55(89)90)59(94)75-44(58(70)93)19-22-54(87)88)73-63(98)57(35(2)83)78-61(96)48-11-8-28-80(48)65(100)46(21-24-56(91)92)77-60(95)47-10-7-27-79(47)53(86)12-3-5-25-72-68(106)74-36-13-16-40-43(29-36)69(104-67(40)102)41-17-14-37(84)30-51(41)103-52-31-38(85)15-18-42(52)69/h13-18,29-31,34-35,39,44-50,57,83-85H,3-12,19-28,32-33,71H2,1-2H3,(H2,70,93)(H,73,98)(H,75,94)(H,76,97)(H,77,95)(H,78,96)(H,87,88)(H,89,90)(H,91,92)(H2,72,74,106)/t34-,35+,39+,44-,45-,46-,47-,48-,49-,50-,57-/m0/s1
Standard InChI Key: UWWKXCTWDRLLID-OZQAYVCASA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1498.59 | Molecular Weight (Monoisotopic): 1497.5758 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Liu F, Stephen AG, Fisher RJ, Burke TR.. (2008) Protected aminooxyprolines for expedited library synthesis: application to Tsg101-directed proline-oxime containing peptides., 18 (3): [PMID:18083557] [10.1016/j.bmcl.2007.12.003] |
Source(1):